Login to Your Account

Other News To Note

Monday, March 7, 2011
MediciNova Inc., of San Diego, and Zhejiang Medicine Co. Ltd., of Hangzhou, China, signed a letter of intent to form a joint venture to develop and commercialize MediciNova's MN-221 in China. Financial terms were not disclosed. MN-221, a selective, beta2-adrenergic receptor agonist, is in development in acute exacerbations of asthma and chronic obstructive pulmonary disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription